As Vice President, Nonclinical Development, Susan Sloan is responsible for IND-enabling activities spanning preclinical, bioanalytical and pharmacology to transition programs from research to the clinic. Susan also currently oversees the Quality function. Susan joined Visterra in 2013 and has over 16 years of biologics drug development experience.
Prior to joining Visterra, Susan worked at MassBiologics, where she held various roles in research, development and quality. While at MassBiologics, she discovered a human monoclonal antibodies directed against the rabies virus Glycoprotein. Her work led to the development of Rabishield, a rabies monoclonal antibody developed in partnership with Serum Institute of India that has been approved for human use in India.
Susan obtained her BS in biology from Pennsylvania State University and her PhD in Genetics from Tufts University Graduate School of Biomedical Sciences where she developed mouse models to explore the development of endocrine cells in the GI tract.